WHO Prequalified, second-generation purified chick embryo cell (PCEC) rabies vaccine with high potency level per dose, recommended for all established WHO intramuscular (IM) and intradermal (ID) vaccination schedule
Contains inactivated rabies virus with a potency of ≥2.5 IU/dose and is suitable for both pre-exposure and post-exposure prophylaxis for all individuals at high-risk from rabies infection
Conforms to the WHO requirements by inducing a rabies virus neutralizing antibodies (RVNA) concentration of ≥0.5 IU/mL which is regarded by the WHO as being an ‘adequate’ protective RVNA concentration, and is commonly used as a threshold in clinical trials
Most widely used rabies vaccine with over 80 million doses sold since its introduction into the world market
